Stocks Health care SMMT
NASDAQ · Health careSummit Therapeutics Inc. (SMMT)
It posted a net loss of $832.7M. In fiscal 2025 capital spending exceeded operating cash flow by $323.6M. At September 30, 2026 it held $150.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Summit Therapeutics Inc.
- Net worth
- Summit Therapeutics Inc. has a market value (market cap) of $14B at the latest share price, and shareholders' equity of $564.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2024 revenue was $0, with a net loss of $221.3M.
- Cash flow
- In fiscal 2025 operations used $322.9M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Summit Therapeutics Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Summit Therapeutics Inc. does
Summit Therapeutics Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SMMT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$1.1B | -$1.44 | -$323.6M |
| 2024 | $0 | -$221.3M | -$0.31 | -$142.2M |
| 2023 | $0 | -$614.9M | -$0.99 | -$76.9M |
| 2022 | $705K | -$78.8M | -$0.41 | -$42.2M |
| 2021 | $1.8M | -$88.6M | -$0.67 | -$72.9M |
| 2020 | $860K | -$52.7M | -$0.53 | -$48.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Summit Therapeutics Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 4, 2026Other event 8-K
- November 4, 2026
- November 4, 2026
- October 19, 2026Proxy statement DEF 14A
- October 6, 2026Preliminary proxy statement PRE 14A
- September 29, 2026Material agreement8-KSummit Therapeutics agreed to sell convertible preferred stock to AstraZeneca for gross proceeds of $2.0 billion and collaborate on cancer clinical trials.
- September 15, 2026Other event 8-K
- September 14, 2026Other event 8-K
- September 3, 2026Other event 8-K
- August 26, 2026Other event 8-K
Insider trades
What the people running Summit Therapeutics Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 1 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 8, 2026 | Anand BhaskarChief Accounting Officer | Received as pay | 100,000 | - |
| June 12, 2026 | Duggan Robert WCo-Chief Executive Officer, Director, 10% owner | Bought | 3,810,000 | $50M |
| June 12, 2026 | Zanganeh MahkamCo-Chief Executive Officer, Director, 10% owner | Boughtindirect | 3,810,000 | $50M |
| June 4, 2026 | Duggan Robert WCo-Chief Executive Officer, Director, 10% owner | Boughtindirect | 100,000 | $1.5M |
| June 4, 2026 | Zanganeh MahkamCo-Chief Executive Officer, Director, 10% owner | Boughtindirect | 100,000 | $1.5M |
| June 4, 2026 | Soni Manmeet SinghCOO and CFO, Director | Bought | 25,000 | $361.5K |
| June 4, 2026 | Soni Manmeet SinghCOO and CFO, Director | Bought | 25,000 | $360.8K |
Who owns SMMT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
Largest institutional holders
Insiders
4 insiders reported holding 1,176,976,882 shares in total, about $20.6B at the last price.
| Holder | Shares |
|---|---|
| Duggan Robert WCo-Chief Executive Officer, Director, 10% owner | 599,708,35325,824,474 held indirectly |
| Zanganeh MahkamCo-Chief Executive Officer, Director, 10% owner | 573,883,879573,883,879 held indirectly |
| Soni Manmeet SinghCOO and CFO, Director | 3,123,603 |
| Anand BhaskarChief Accounting Officer | 261,047 |
Questions about SMMT
What does Summit Therapeutics Inc. do?
Summit Therapeutics Inc. is a company in the Health care sector, listed on NASDAQ as SMMT. Its shares trade on NASDAQ under the ticker SMMT.
What is Summit Therapeutics Inc.'s net worth?
Summit Therapeutics Inc. has a market value (market cap) of $14B at the latest share price, and shareholders' equity of $564.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Summit Therapeutics Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $832.7M.
When did Summit Therapeutics Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026.
When is Summit Therapeutics Inc.'s next earnings report?
Summit Therapeutics Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare SMMT with
Follow SMMT
Get an email when Summit Therapeutics Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Summit Therapeutics Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.